The US Food and Drug Administration won’t penalize manufacturers of non-invasive fetal and maternal monitoring devices if they make changes to their products so they can be used in a home setting during the COVID-19 pandemic.
That’s the message from an immediately-in-effect guidance document released by the agency on 23 April, “Enforcement Policy for Non-Invasive...